The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses that Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

The Thai HIV phase III prime-boost trial (RV144) using ALVAC-HIV(®) (vCP1521) and AIDSVAX B/E(®) was, to our knowledge, the first to demonstrate acquisition efficacy. Vaccine-induced, cell-mediated immune responses were assessed. T cell epitope mapping studies using IFN-γ ELISPOT were performed on P...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: de Souza, Mark S., Ratto-Kim, Silvia, Chuenarom, Weerawan, Schuetz, Alexandra, Chantakulkij, Somsak, Nuntapinit, Bessara, Valencia-Micolta, Anais, Thelian, Doris, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Paris, Robert M., Kaewkungwal, Jaranit, Michael, Nelson L., Rerks-Ngarm, Supachai, Mathieson, Bonnie, Marovich, Mary, Currier, Jeffrey R., Kim, Jerome H.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2012
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383859/
https://ncbi.nlm.nih.gov/pubmed/22529301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1102756
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים